Published in Cancer Epidemiol Biomarkers Prev on February 01, 2005
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol (2009) 1.17
Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med (2014) 1.12
Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila) (2011) 1.08
Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J (2009) 1.07
Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate (2010) 1.06
Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev (2011) 1.04
Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol (2010) 1.02
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer (2012) 0.96
The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol (2009) 0.92
Aspirin and urologic cancer risk: an update. Nat Rev Urol (2012) 0.91
p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate (2010) 0.89
Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol (2014) 0.86
The diet as a cause of human prostate cancer. Cancer Treat Res (2014) 0.86
Positive correlation between PEDF expression levels and macrophage density in the human prostate. Prostate (2012) 0.84
Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. Biomed Res Int (2015) 0.77
Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies. Cancer Causes Control (2016) 0.75
NSAIDs and Cell Proliferation in Colorectal Cancer. Pharmaceuticals (Basel) (2010) 0.75
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals (Basel) (2010) 0.75
Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Med (2017) 0.75
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Complications after prostate biopsy: data from SEER-Medicare. J Urol (2011) 5.40
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Hearing loss and incident dementia. Arch Neurol (2011) 4.65
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care (2007) 4.14
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol (2012) 4.11
Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst (2010) 3.98
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol (2004) 2.91
Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med (2007) 2.88
Meat consumption and prospective weight change in participants of the EPIC-PANACEA study. Am J Clin Nutr (2010) 2.87
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Hearing loss and cognition in the Baltimore Longitudinal Study of Aging. Neuropsychology (2011) 2.54
Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol (1985) (2006) 2.50
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials (2009) 2.49
Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2010) 2.47
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Biomarkers of caloric restriction may predict longevity in humans. Science (2002) 2.32
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke (2009) 2.28
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol (2007) 2.02
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2007) 1.98
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ (2011) 1.94
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol (2008) 1.78
A home-based pedometer-driven walking program to increase physical activity in older adults with osteoarthritis of the knee: a preliminary study. J Am Geriatr Soc (2003) 1.76
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab (2006) 1.71
Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab (2002) 1.70
Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab (2007) 1.70
Survival following a diagnosis of Alzheimer disease. Arch Neurol (2002) 1.69
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer (2007) 1.64
Neuropsychological data in nondemented oldest old: the 90+ Study. J Clin Exp Neuropsychol (2007) 1.63
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Activity restriction induced by fear of falling and objective and subjective measures of physical function: a prospective cohort study. J Am Geriatr Soc (2008) 1.60